1-benzenesulfonyl-4-isopropyl-piperazine | 100800-52-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzenesulfonyl-4-isopropyl-piperazine
• 英文别名: 1-Benzolsulfonyl-4-isopropyl-piperazin；1-(Benzenesulfonyl)-4-propan-2-ylpiperazine
• CAS: 100800-52-0
• 化学式: C₁₃H₂₀N₂O₂S
• mdl: MFCD02177351
• 分子量: 268.38
• InChiKey: ZHOBXESVWFXOGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N,N-二(2-氯乙基)苯磺酰胺 、 异丙胺 在 乙醇 作用下， 生成 1-benzenesulfonyl-4-isopropyl-piperazine
  参考文献：
  名称：

  1-alkylsulfonyl-4-alkyl piperazines

  摘要：

  公开号：

  US02507408A1

文献信息

• QUINOLINE COMPOUNDS AND METHODS OF USE
  申请人：Gaudino John

  公开号：US20110053931A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、盐和药学上可接受的前药，用于抑制受体酪氨酸激酶并治疗由此介导的过度增殖性疾病。本文揭示了使用式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• INHIBITORS OF PLASMA KALLIKREIN
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20160168123A1

  公开（公告）日：2016-06-16

  The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.

  本发明提供了式(I)的化合物、包含这些化合物的组合物；以及这些化合物在治疗中的应用（例如在涉及血浆卡利肯酶活性的疾病或病状的治疗或预防中）；以及使用这些化合物治疗患者的方法；其中R5、R6、R7、R12、R13、A、L、B、n、W、X、Y和Z如本文所定义。
• Inhibitors of plasma kallikrein
  申请人：Kalvista Pharmaceuticals Limited

  公开号：US10221161B2

  公开（公告）日：2019-03-05

  The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.

  本发明提供了式 (I) 化合物、包含此类化合物的组合物；此类化合物在治疗中的用途（例如在治疗或预防血浆卡利克瑞因活性涉及的疾病或病症中的用途）；以及用此类化合物治疗患者的方法；其中 R5、R6、R7、R12、R13、A、L、B、n、W、X、Y 和 Z 如本文所定义。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10308614B2

  公开（公告）日：2019-06-04

  The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

  本发明涉及式（I）化合物： 及其盐类，其中R1-R4具有说明书中定义的任何值，以及其组合物和用途。这些化合物可用作 BRG1、BRM 和/或 PB1 的抑制剂。还包括包含式（I）化合物或其药学上可接受的盐的药物组合物，以及使用此类化合物和盐治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180086720A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I): and salts thereof, wherein: R 1 -R 4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.